Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1990 1
1991 1
1992 2
1993 5
1994 6
1995 1
1996 8
1997 9
1998 10
1999 11
2000 16
2001 20
2002 20
2003 22
2004 38
2005 40
2006 59
2007 69
2008 69
2009 101
2010 107
2011 139
2012 163
2013 186
2014 209
2015 206
2016 207
2017 242
2018 279
2019 301
2020 421
2021 483
2022 513
2023 486
2024 621
2025 617
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,184 results

Results by year

Filters applied: . Clear all
Page 1
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.
Qi C, Liu C, Peng Z, Zhang Y, Wei J, Qiu W, Zhang X, Pan H, Niu Z, Qiu M, Qin Y, Fang W, Ye F, Li N, Liu T, Liu A, Zhang X, Hu C, Zhang J, Cui J, Lin X, Wang S, Zhang J, Lin T, Qu X, Yuan X, Gong J, Li J, Gao W, Gai L, Wang Y, Yuan D, Li Z, Shen L. Qi C, et al. Among authors: ye f. Lancet. 2025 Jun 7;405(10494):2049-2060. doi: 10.1016/S0140-6736(25)00860-8. Epub 2025 May 31. Lancet. 2025. PMID: 40460847 Clinical Trial.
First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study.
Qin S, Bai Y, Li J, Pan H, Luo S, Qu Y, Ye F, Yang L, Liu T, Li W, Chen X, Yang J, Ying J, Lin X, Zhao L, Liang X, Mao Y, Guo R, Zuo Y, Bordia S, Li S. Qin S, et al. Among authors: ye f. Adv Ther. 2025 Apr;42(4):1892-1906. doi: 10.1007/s12325-024-03069-4. Epub 2025 Mar 1. Adv Ther. 2025. PMID: 40025394 Free PMC article. Clinical Trial.
The TRIP12 E3 ligase induces SWI/SNF component BRG1-β-catenin interaction to promote Wnt signaling.
Kassel S, Yuan K, Bunnag N, Neitzel LR, Lu W, Schwarzkopf A, Maines B, Loberg MA, Xu G, Adams A, McCray AD, Cho A, Rockouski M, Orton G, Goldsmith L, Aronno MMA, Spencer ZT, Khan OM, Ye F, Williams C, Lebensohn AM, Rohatgi R, Wang X, Weiss VL, Hong CC, Kettenbach AN, Robbins DJ, Ahmed Y, Lee E. Kassel S, et al. Among authors: ye f. Nat Commun. 2025 Jun 5;16(1):5248. doi: 10.1038/s41467-025-60535-5. Nat Commun. 2025. PMID: 40473626 Free PMC article.
Expert consensus on cancer treatment-related lung injury.
Lin X, Guo H, Zhao W, Li M, Lin G, Chu Q, Chen E, Chen L, Chen R, Chu T, Deng H, Deng Y, Dong H, Dong W, Dong Y, Fang W, Gan X, Gong L, Gu Y, Han Q, Hao Y, He Y, Hu C, Hu J, Hu Y, Jiang Y, Jin Y, Lan F, Li W, Li W, Liang W, Liu A, Liu D, Liu M, Liu M, Liu Z, Liu Z, Luo Q, Miao L, Mu C, Pan P, Peng P, Qin J, Qin Y, Shen P, Shi M, Song Y, Su C, Su J, Su X, Tan X, Tang K, Tang X, Tian P, Wang B, Wang H, Wang K, Wang M, Wang Q, Wang W, Wang Z, Wu D, Xu F, Xu Y, Xu C, Xie Z, Xie X, Yang B, Yang M, Ye F, Ye X, Yu Z, Zhang J, Zhang J, Zhang X, Zhao F, Zheng X, Zhu B, Zhu Z, Zhou J, Zhou J, Zhou M, Zhou Q, Zou Z, Kidane B, Bignami E, Sakamaki F, Roviello G, Taniguchi H, Jeon K, Saric L, Ariza-Prota M, La-Beck NM, Kanaji N, Watanabe S, Shukuya T, Akaba T, Leong TL, Gesierich W, Koga Y, Tanino Y, Uehara Y, Li S, Chen R, Zhou C. Lin X, et al. Among authors: ye f. J Thorac Dis. 2025 Apr 30;17(4):1844-1875. doi: 10.21037/jtd-2025-292. Epub 2025 Apr 28. J Thorac Dis. 2025. PMID: 40400937 Free PMC article. Review.
5,184 results